New blood test detects early ovarian cancer
There are no reliable blood tests for these patients, and existing invasive tests often miss early-stage ovarian tumours, the researchers wrote in Cancer Research Communications.
Using machine learning tools, the researchers identified multiple biomarkers - from across a wide range of molecules and processes in the body - that could be combined into a single test that detects all sub-types of the disease, at all stages.
Tested at a large medical centre on blood samples from nearly 400 women with possible symptoms of ovarian cancer, the test was 92 percent accurate at identifying those with any stage of ovarian cancer and 88 percent accurate at identifying those with Stage I or Stage II disease, according to the report.
Oriana Papin-Zoghbi, chief executive officer of the company developing the new test -Denver, Colorado-based AOA Dx - said the findings show its potential to aid 'in making faster, more informed decisions for women who need urgent clarity during a challenging diagnostic process.'
Ovarian cancer is the fifth leading cause of cancer-related deaths among women, largely due to delays in diagnosis until after the disease has spread in the body, at which point it's harder to treat.
More than 90 percent of patients with early-stage ovarian cancer experience symptoms that can be mistaken for benign conditions, such as bloating, abdominal pain, and digestive issues.
WAM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Today
15 hours ago
- Gulf Today
New blood test detects early ovarian cancer
An experimental blood test detected early-stage ovarian cancer in patients with vague symptoms that would likely be misdiagnosed using currently available methods, researchers said in a new report. There are no reliable blood tests for these patients, and existing invasive tests often miss early-stage ovarian tumours, the researchers wrote in Cancer Research Communications. Using machine learning tools, the researchers identified multiple biomarkers - from across a wide range of molecules and processes in the body - that could be combined into a single test that detects all sub-types of the disease, at all stages. Tested at a large medical centre on blood samples from nearly 400 women with possible symptoms of ovarian cancer, the test was 92 percent accurate at identifying those with any stage of ovarian cancer and 88 percent accurate at identifying those with Stage I or Stage II disease, according to the report. Oriana Papin-Zoghbi, chief executive officer of the company developing the new test -Denver, Colorado-based AOA Dx - said the findings show its potential to aid 'in making faster, more informed decisions for women who need urgent clarity during a challenging diagnostic process.' Ovarian cancer is the fifth leading cause of cancer-related deaths among women, largely due to delays in diagnosis until after the disease has spread in the body, at which point it's harder to treat. More than 90 percent of patients with early-stage ovarian cancer experience symptoms that can be mistaken for benign conditions, such as bloating, abdominal pain, and digestive issues. WAM
Broadcast Pro
4 days ago
- Broadcast Pro
Turkey to send twin micro rovers to Moon in China-led mission
The mission, led by Ankaras Middle East Technical University in collaboration with Zhejiang University and Chinese private space-tech company Star Vision, is scheduled for launch in 2028. Middle East Technical University (ODTÜ) is set to make space history as two autonomous micro rovers developed by the university will be deployed to the Moons South Pole under Chinas Change-8 mission, marking Türkiye as the first country to land and operate two rovers simultaneously on the lunar surface. The AI-driven rovers, named CHERI (Challenging Environment Exploration Robot for Intelligence), each weigh about five kilograms and are roughly the size of a shoebox. Engineered to withstand the Moons extreme conditions, they will autonomously conduct 3D mapping, measure temperature and radiation levels, and share navigational data with one another. In a pioneering mission feature, the rovers will be deployed on separate days, with the second recording the firsts descent, a never-before-attempted technique in lunar exploration that is expected to yield unique visual documentation and scientific insight. Developed in partnership with China-based Star Vision and Zhejiang University, the project underscores Türkiyes growing role in global space collaboration. ODTÜ Rector Ahmet Yozgatl?gil emphasised that the mission reflects both national ambition in space research and a commitment to international scientific cooperation, aiming to build a competitive, independent and innovation-driven ecosystem for the countrys future. Researchers from ODTÜs main campus in Ankara and its Turkish Cyprus campus have contributed to the mission, with the latter developing a scientific payload to support the search for water on the Moon. The Turkish Cyprus campus is also spearheading advances in the digital field, having launched the countrys first undergraduate program in Cybersecurity Engineering in 2025.
Al Etihad
4 days ago
- Al Etihad
Renowned orthopaedic experts bring advanced care to Abu Dhabi in August
11 Aug 2025 22:33 SAMIHAH ZAMAN (ABU DHABI)Patients looking for world-class orthopaedic care close to home can benefit from a duo of doctors headed to Abu Dhabi as part of the Department of Health – Abu Dhabi's (DoH) Visiting Physicians Munjed Al Muderis, a US-based consultant in orthopaedic surgery and Singapore-based Dr. Aymeric Lim, senior consultant of hand and reconstructive microsurgery, are seeing patients at two healthcare facilities in the capital, the DoH has announced. 'The DoH welcomes top-tier doctors from around the world to the Emirate during August, offering exceptions healthcare services through the Visiting Physicians Programme,' the authority announced. Dr. Munjed Al Muderis (L) and Dr. Aymeric Lim (R) Al Muderis practises at the St Mary Hosptial, Paley Institute at West Palm Beach, one of the largest centres in orthopaedics and limb lengthening in the United States. He specialises in limb lengthening, the treatment of diabetic feet, osseointegration for amputees, limb reconstruction, joint replacement, bone tumour treatment and paediatric orthopaedics. According to the DoH, he will see patients at the Burjeel Medical City between August 11 and part of the National University Hospital in Singapore, has 30 years of experience in micro hand surgeries, nerve surgery, tendon transfer, and the treatment of patients with severe crush or nerve injuries in the forearm. He will offer treatment services at the Sheikh Shakhbout Medical City between August 11 and DoH has urged patients and their families to directly contact the respective hospitals in order to book appointments. The authority's Visiting Physicians Programme – launched in 2021 with the aim of providing world-class care in Abu Dhabi – had enabled the treatment of over 3,200 patients in the emirate as of December 2024. Source: Aletihad - Abu Dhabi
